tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Trevi Therapeutics price target lowered to $27 from $29 at Raymond James
PremiumThe FlyTrevi Therapeutics price target lowered to $27 from $29 at Raymond James
29d ago
Promising Phase 2b Results and Strong Financial Position Drive Buy Rating for Trevi Therapeutics
Premium
Ratings
Promising Phase 2b Results and Strong Financial Position Drive Buy Rating for Trevi Therapeutics
29d ago
Trevi Therapeutics Reports Positive Trial Results and Financial Stability
Premium
Company Announcements
Trevi Therapeutics Reports Positive Trial Results and Financial Stability
29d ago
Trevi Therapeutics: Positive Developments and Financial Strength Support Buy Rating
PremiumRatingsTrevi Therapeutics: Positive Developments and Financial Strength Support Buy Rating
3M ago
Trevi Therapeutics Announces Public Offering Pricing
Premium
Company Announcements
Trevi Therapeutics Announces Public Offering Pricing
3M ago
Trevi Therapeutics 17.4M share Secondary priced at $5.75
Premium
The Fly
Trevi Therapeutics 17.4M share Secondary priced at $5.75
3M ago
Trevi Therapeutics price target raised to $23 from $20 at Oppenheimer
PremiumThe FlyTrevi Therapeutics price target raised to $23 from $20 at Oppenheimer
3M ago
Trevi Therapeutics announces $100M common stock offering
Premium
The Fly
Trevi Therapeutics announces $100M common stock offering
3M ago
Buy Rating for Trevi Therapeutics Driven by Promising Haduvio Trial Results and Market Opportunities
Premium
Ratings
Buy Rating for Trevi Therapeutics Driven by Promising Haduvio Trial Results and Market Opportunities
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100